CN Patent

CN114727999A — 用于预防hiv的衣壳抑制剂

Assigned to Gilead Sciences Inc · Expires 2022-07-08 · 4y expired

What this patent protects

本公开提供了预防受试者的HIV的方法，所述方法包括任选地与一种或多种附加治疗剂组合向所述受试者施用治疗有效量的式(Ia)或(Ib)化合物：或其药学上可接受的盐。还提供了降低感染HIV(例如，HIV‑1和/或HIV‑2)的风险的方法。

USPTO Abstract

本公开提供了预防受试者的HIV的方法，所述方法包括任选地与一种或多种附加治疗剂组合向所述受试者施用治疗有效量的式(Ia)或(Ib)化合物：或其药学上可接受的盐。还提供了降低感染HIV(例如，HIV‑1和/或HIV‑2)的风险的方法。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN114727999A
Jurisdiction: CN
Classification: —
Expires: 2022-07-08
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.